| Fidaxomicin versus Vancomycin for Clostridium difficile Infection TJ Louie, MA Miller, KM Mullane, K Weiss, A Lentnek, Y Golan, S Gorbach, ... New England Journal of Medicine 364 (5), 422-431, 2011 | 1939 | 2011 |
| Prior environmental contamination increases the risk of acquisition of vancomycin-resistant enterococci M Drees, DR Snydman, CH Schmid, L Barefoot, K Hansjosten, PM Vue, ... Clinical infectious diseases 46 (5), 678-685, 2008 | 412 | 2008 |
| Efficacy of Fidaxomicin Versus Vancomycin as Therapy for Clostridium difficile Infection in Individuals Taking Concomitant Antibiotics for Other Concurrent Infections KM Mullane, MA Miller, K Weiss, A Lentnek, Y Golan, PS Sears, YK Shue, ... Clinical infectious diseases 53 (5), 440-447, 2011 | 309 | 2011 |
| Factors Associated with Candidemia Caused by Non-albicans Candida Species Versus Candida albicans in the Intensive Care Unit JK Chow, Y Golan, R Ruthazer, AW Karchmer, Y Carmeli, D Lichtenberg, ... Clinical infectious diseases 46 (8), 1206-1213, 2008 | 296 | 2008 |
| Listeria monocytogenes infection in Israel and review of cases worldwide Y Siegman-Igra, R Levin, M Weinberger, Y Golan, D Schwartz, Z Samra, ... Emerging infectious diseases 8 (3), 305, 2002 | 292 | 2002 |
| Reappraisal of community-acquired bacteremia: a proposal of a new classification for the spectrum of acquisition of bacteremia SI Yardena, F Boaz, OW Ruth, G Yoav, N Aliza, S David, G Michael Clinical infectious diseases 34 (11), 1431-1439, 2002 | 276 | 2002 |
| National Survey on the Susceptibility of Bacteroides fragilis Group: Report and Analysis of Trends in the United States from 1997 to 2004 DR Snydman, NV Jacobus, LA McDermott, R Ruthazer, Y Golan, ... Antimicrobial agents and chemotherapy 51 (5), 1649-1655, 2007 | 204 | 2007 |
| Lessons learned from the anaerobe survey: historical perspective and review of the most recent data (2005–2007) DR Snydman, NV Jacobus, LA McDermott, Y Golan, DW Hecht, ... Clinical Infectious Diseases 50 (Supplement_1), S26-S33, 2010 | 202 | 2010 |
| Risk factors for albicans and non-albicans candidemia in the intensive care unit JK Chow, Y Golan, R Ruthazer, AW Karchmer, Y Carmeli, DA Lichtenberg, ... Critical care medicine 36 (7), 1993-1998, 2008 | 194 | 2008 |
| Derivation and validation of a simple clinical bedside score (ATLAS) for Clostridium difficile infection which predicts response to therapy MA Miller, T Louie, K Mullane, K Weiss, A Lentnek, Y Golan, Y Kean, ... BMC infectious diseases 13, 1-7, 2013 | 156 | 2013 |
| Candidaemia associated with decreased in vitro fluconazole susceptibility: is Candida speciation predictive of the susceptibility pattern? DA Oxman, JK Chow, G Frendl, S Hadley, S Hershkovitz, P Ireland, ... Journal of antimicrobial chemotherapy 65 (7), 1460-1465, 2010 | 153 | 2010 |
| The Impact of Cirrhosis on CD4+ T Cell Counts in HIV-Seronegative Patients BH McGovern, Y Golan, M Lopez, D Pratt, A Lawton, G Moore, M Epstein, ... Clinical Infectious Diseases 44 (3), 431-437, 2007 | 153 | 2007 |
| Efficacy and safety of ridinilazole compared with vancomycin for the treatment of Clostridium difficile infection: a phase 2, randomised, double-blind, active-controlled, non … RJ Vickers, GS Tillotson, R Nathan, S Hazan, J Pullman, C Lucasti, ... The Lancet infectious diseases 17 (7), 735-744, 2017 | 150 | 2017 |
| Appraising contemporary strategies to combat multidrug resistant gram-negative bacterial infections–proceedings and data from the Gram-Negative Resistance Summit MH Kollef, Y Golan, ST Micek, AF Shorr, MI Restrepo Clinical infectious diseases 53 (suppl_2), S33-S55, 2011 | 138 | 2011 |
| Update on resistance of Bacteroides fragilis group and related species with special attention to carbapenems 2006–2009 DR Snydman, NV Jacobus, LA McDermott, Y Golan, EJC Goldstein, ... Anaerobe 17 (4), 147-151, 2011 | 136 | 2011 |
| Long-term serological analysis and clinical follow-up of patients with cat scratch disease E Metzkor-Cotter, Y Kletter, B Avidor, M Varon, Y Golan, M Ephros, ... Clinical infectious diseases 37 (9), 1149-1154, 2003 | 136 | 2003 |
| Effect of subcutaneous casirivimab and imdevimab antibody combination vs placebo on development of symptomatic COVID-19 in early asymptomatic SARS-CoV-2 infection: a randomized … MP O’Brien, E Forleo-Neto, N Sarkar, F Isa, P Hou, KC Chan, BJ Musser, ... Jama 327 (5), 432-441, 2022 | 108 | 2022 |
| Molecular diagnosis of cat scratch disease: a two-step approach B Avidor, Y Kletter, S Abulafia, Y Golan, M Ephros, M Giladi Journal of clinical microbiology 35 (8), 1924-1930, 1997 | 107 | 1997 |
| Empirical Anti-Candida Therapy among Selected Patients in the Intensive Care Unit: A Cost-Effectiveness Analysis Y Golan, MP Wolf, SG Pauker, JB Wong, S Hadley Annals of internal medicine 143 (12), 857-869, 2005 | 105 | 2005 |
| OPT-80-003 Clinical Study Group Fidaxomicin versus vancomycin for Clostridium difficile infection TJ Louie, MA Miller, KM Mullane, K Weiss, A Lentnek, Y Golan, S Gorbach, ... N Engl J Med 364 (5), 422-431, 2011 | 99 | 2011 |
